• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

U.K. says doctors should limit use of paclitaxel devices

June 4, 2019 By Nancy Crotti

MHRAU.K. medtech regulators have recommended a ban on routine use of paclitaxel drug-coated balloons (DCBs) and drug-eluting stents in patients with intermittent leg cramps, but held back on recommending the same for patients with critical limb ischemia.

U.S., U.K. and French regulators began raising concerns about the risk of increased long-term mortality in people with peripheral artery disease who were treated with paclitaxel-coated devices compared to those treated with bare devices following the December publication of a meta-analysis of patient outcomes.

U.K. and French regulators began investigations in March after the FDA told doctors that a preliminary review of long-term follow-up data found a “potentially concerning signal” of increased long-term mortality in people with peripheral artery disease who were treated with paclitaxel-coated devices.

In January, the FDA said that it plans to assess long-term follow-up data from studies that supported the approval of paclitaxel-coated balloons or paclitaxel-eluting stents in the U.S. The agency is focusing on causes of death within these studies, paclitaxel dose delivered and patient characteristics.

U.K. regulators said the risk of mortality from using the paclitaxel-coated balloons and stents in leg-cramp patients “generally outweighs the benefits,” while the benefits outweigh the risk of using the devices in critical limb ischemia patients. “This is because these patients generally have a higher risk of irreversible ischemic damage resulting from restenosis, and a lower life expectancy,” the Medicines and Healthcare Products Regulatory Agency (MHRA) said in a news release.

The MHRA also recommended that healthcare providers assess the relative risks on an individual patient basis, provide informed consent, “enhanced life-long follow-up” and report any serious adverse events and cause of death.

The FDA and French regulators are continuing to investigate the possibility of a link between the use of paclitaxel-coated balloons and stents and increased mortality over two to five years. MHRA said it will review the need to update its advice as further evidence emerges.

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: FDA, Medicines and Healthcare Products Regulatory Agency, MHRA

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS